Medicines for Maternal Health

Key Data and Findings

No. of pages: 37

Publication Date: 2012

Author: UNFPA

Expanding access to quality, affordable maternal health medicines is critical to making progress in reducing maternal mortality. However, significant challenges often impede such access. Chief among them is a lack of data on the needs, gaps, systems and financing for maternal health medicines.

This report, prepared for the United Nations Commission on Commodities for Women and Children’s Health, provides a review of the current conditions and available evidence on maternal health medicines, specifically Oxytocin and Misoprostol to prevent post-partum haemorrhage and magnesium sulfate, considered the safest, most effective, and lowest-cost medication for treating pre-eclampsia and eclampsia.

The report also includes 11 priority issues for actions

Under the auspices of the United Nations Secretary-General’s Every Woman Every Child initiative, the Commission on Life-Saving Commodities for Women and Children advocates at the highest levels for the increased availability, affordability and accessibility of essential but underutilized commodities for maternal and child health.

 

Related content

News
UNFPA delivered critical supplies to a remote settlement in Rukban, where residents have been stranded in the desert for years.
News
In the aftermath of the powerful earthquake that struck the Iraq-Iran border on 12 November, UNFPA has scaled up its emergency response to meet the needs of women and girls.
News
Motherhood should be a time of joy, but for too many women, it comes with something else: peril. "Becoming a mother and having a family was always a dream of mine.

Pages

We use cookies and other identifiers to help improve your online experience. By using our website you agree to this. To learn more, including how to change your settings, see our cookies policy.

X